OtherClinical Investigations
New Advances in Peptide Receptor Radionuclide Therapy
Marion de Jong and Eric Krenning
Journal of Nuclear Medicine May 2002, 43 (5) 617-620;
In this issue
New Advances in Peptide Receptor Radionuclide Therapy
Marion de Jong, Eric Krenning
Journal of Nuclear Medicine May 2002, 43 (5) 617-620;
Jump to section
Related Articles
- No related articles found.
Cited By...
- NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
- 90Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy
- SSTR-Mediated Imaging in Breast Cancer: Is There a Role for Radiolabeled Somatostatin Receptor Antagonists?
- 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function
- Diabody Pretargeting with Click Chemistry In Vivo
- Treatment of Metastatic Carcinoid Tumors With Radiolabeled Biologic Molecules
- Use of Polyglutamic Acids to Reduce Uptake of Radiometal-Labeled Minigastrin in the Kidneys
- Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors
- Combination Radionuclide Therapy Using 177Lu- and 90Y-Labeled Somatostatin Analogs
- Radiotargeted Gene Therapy
- Long-Term Efficacy of Radionuclide Therapy in Patients with Disseminated Neuroendocrine Tumors Uncontrolled by Conventional Therapy
- Uptake of [111In-DTPA0]Octreotide in the Rat Kidney Is Inhibited by Colchicine and Not by Fructose